脑电生物反馈治疗慢性精神分裂症伴发焦虑障碍的疗效及安全性研究

摘要

Objective: To observe efficacy and the safety of EEG biofeedback for chronic schizophrenia with anxiety disorders. Methods: 78 cases of patients with schizophrenia were randomly divided into control group and observation group with 39 cases each group. Both groups maintained daily medication, while the observation group was given EEG biofeedback. Before and 8 weeks after the treatment,the efficacy was measured by self-rating anxiety scale(SAS), scale for assessment of negative symptoms(SANS), and scale for assessment of positive symptoms (SAPS); and safety was assessed by treatment emergent symptom scale(TESS) and other records of adverse events. Results: Compared with control group, the observation group had lower SAS scores and SANS scores (P<0. 05);however, no decrease of SAPS scores was observed(P>0. 05). There were no serious adverse events during the treatment. Conclu-sions: EEG biofeedback treatment can improve to a certain extent anxiety symptoms of the schizophrenic patients, improve the social interest and negative symptoms, is safe and effective, and is worth being clinically popularized widely.%目的：：观察脑电生物反馈治疗对慢性精神分裂症患者伴发焦虑障碍的疗效和安全性。方法：将78例精神分裂症患者随机分成对照组和观察组,每组各39例。两组患者均维持日常药物治疗,对照组患者同时给予脑电生物反馈治疗。治疗前及8周后,两组患者间根据焦虑自评量表(SAS)、阴性性症状量表(SANS)、阳性症状量表(SAPS)评定,观察疗效。通过副反应量表(TESS)和其它不良事件的描述性资料,评价安全性。结果：与对照组相比,观察组患者治疗后的 SAS 评分、SANS 评分明显降低(P<0.05),SAPS 评分无明显降低(P>0.05)。治疗期间没有出现严重不良反应。结论：脑电生物反馈治疗能在一定程度上改善精神分裂症患者焦虑症状,提高社交兴趣,改善阴性症状,且安全有效,不良反应少,值得临床推广。